&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-02-26, 14:05

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Cassie Shields

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-02-11, 15:06

Nemysis Limited Announces Successful IHAT-Gut Trial

DUBLIN, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Nemysis is pleased to announce the publication of the successful findings from the IHAT-Gut trial in...

Popular Posts